IRRAS.ST
IRRAS AB (publ) [IRRAS.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
IRRAS.ST Stock Summary
In the News
IRRAS.ST Financial details
Company Rating
Sell
Market Cap
181.75M
Income
-194.6M
Revenue
43.1M
Book val./share
0.05
Cash/share
0.02
Dividend
-
Dividend %
-
Employees
47
Optionable
No
Shortable
Yes
Earnings
14 Feb 2024
P/E
-0.66
Forward P/E
-
PEG
0.08
P/S
4.22
P/B
2.96
P/C
8.02
P/FCF
-0.94
Quick Ratio
0.25
Current Ratio
1.29
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.42
EPS next Y
-
EPS next Q
-
EPS this Y
-72.49%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-22.5%
Revenue last 5Y
46.17%
Revenue Q/Q
-8.04%
EPS Q/Q
-31.14%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-202%
ROE
-165%
ROC
-4.57%
Gross Margin
-2%
Oper. Margin
-458%
Profit Margin
-452%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.1125-0.598
52W High
-
52W Low
-
RSI
37
Rel Volume
2.63
Avg Volume
551.32K
Volume
1.45M
Perf Week
-0.74%
Perf Month
-
Perf Quarter
-
Perf Half Y
-5.09%
-
-
-
-
Beta
1.733
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.1604
Change
-0.99%
IRRAS.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.08 | 0.07 | 0.05 | 0.31 | 0.12 | |
| Net income per share | -1.86 | -1.9 | -0.84 | -1.89 | -0.52 | |
| Operating cash flow per share | -1.31 | -1.93 | -0.82 | -1.81 | -0.55 | |
| Free cash flow per share | -1.51 | -2.13 | -0.87 | -1.91 | -0.56 | |
| Cash per share | 1.04 | 1.07 | 0.84 | 0.79 | 0.22 | |
| Book value per share | 2.47 | 1.65 | 1.12 | 1.55 | 0.46 | |
| Tangible book value per share | 1.93 | 1.1 | 0.88 | 1.07 | 0.37 | |
| Share holders equity per share | 2.47 | 1.65 | 1.12 | 1.55 | 0.46 | |
| Interest debt per share | 0 | 0.08 | 0.03 | 0.05 | 0.02 | |
| Market cap | 2.57B | 1.86B | 1.36B | 281.33M | 150.91M | |
| Enterprise value | 2.52B | 1.84B | 1.23B | 229.15M | 87.99M | |
| P/E ratio | -18.5 | -12.3 | -10 | -2.06 | -0.91 | |
| Price to sales ratio | 428.49 | 351.69 | 183.86 | 12.57 | 3.77 | |
| POCF ratio | -26.36 | -12.1 | -10.24 | -2.16 | -0.86 | |
| PFCF ratio | -22.88 | -10.99 | -9.61 | -2.04 | -0.84 | |
| P/B Ratio | 13.95 | 14.15 | 7.45 | 2.52 | 1.03 | |
| PTB ratio | 13.95 | 14.15 | 7.45 | 2.52 | 1.03 | |
| EV to sales | 420.61 | 347.25 | 166.05 | 10.24 | 2.2 | |
| Enterprise value over EBITDA | -19.31 | -13.27 | -10.29 | -1.92 | -0.59 | |
| EV to operating cash flow | -25.88 | -11.94 | -9.25 | -1.76 | -0.5 | |
| EV to free cash flow | -22.46 | -10.86 | -8.68 | -1.66 | -0.49 | |
| Earnings yield | -0.05 | -0.08 | -0.1 | -0.48 | -1.1 | |
| Free cash flow yield | -0.04 | -0.09 | -0.1 | -0.49 | -1.19 | |
| Debt to equity | 0 | 0.05 | 0.02 | 0.03 | 0.04 | |
| Debt to assets | 0 | 0.04 | 0.02 | 0.03 | 0.04 | |
| Net debt to EBITDA | 0.36 | 0.17 | 1.1 | 0.44 | 0.42 | |
| Current ratio | 4.03 | 4.21 | 6.17 | 4.46 | 6.96 | |
| Interest coverage | -895.8 | -1.05K | -355.33 | -1.64K | -599.03 | |
| Income quality | 0.68 | 1.01 | 0.99 | 0.96 | 1.05 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 7.43 | 8.6 | 5.81 | 1.76 | 1.66 | |
| Research and developement to revenue | 3.83 | 5.64 | 3.92 | 1.06 | 1.15 | |
| Intangibles to total assets | 0.2 | 0.28 | 0.19 | 0.26 | 0.15 | |
| Capex to operating cash flow | 0.15 | 0.1 | 0.07 | 0.06 | 0.02 | |
| Capex to revenue | -2.47 | -2.91 | -1.17 | -0.32 | -0.09 | |
| Capex to depreciation | -1.82 | -1.23 | -0.53 | -0.43 | -0.2 | |
| Stock based compensation to revenue | 1.24 | 0.42 | -0.05 | 0.05 | 0.02 | |
| Graham number | 10.19 | 8.41 | 4.59 | 8.11 | 2.31 | |
| ROIC | -0.81 | -1.06 | -0.71 | -1.15 | -1.05 | |
| Return on tangible assets | -0.84 | -1.32 | -0.8 | -1.39 | -1.14 | |
| Graham Net | 0.81 | 0.89 | 0.75 | 0.75 | 0.27 | |
| Working capital | 62.84M | 81.89M | 137.51M | 72M | 117.18M | |
| Tangible asset value | 143.85M | 87.04M | 142.54M | 76.98M | 120.01M | |
| Net current asset value | 62.47M | 79.87M | 137.44M | 71.84M | 111.26M | |
| Invested capital | 0 | 0.05 | 0.02 | 0.03 | 0.04 | |
| Average receivables | 20.76M | 5.38M | 6.44M | 10.66M | 26.86M | |
| Average payables | 5.46M | 8.05M | 5.47M | 4.45M | 6.27M | |
| Average inventory | 7.78M | 8.9M | 16.26M | 15.22M | 20.76M | |
| Days sales outstanding | 178.85 | 539.91 | 249.72 | 265.15 | 341.75 | |
| Days payables outstanding | 157.75 | 71.03 | 53.61 | 39.56 | 81.75 | |
| Days of inventory on hand | 61.3 | 137.11 | 280.88 | 89.63 | 336.28 | |
| Receivables turnover | 2.04 | 0.68 | 1.46 | 1.38 | 1.07 | |
| Payables turnover | 2.31 | 5.14 | 6.81 | 9.23 | 4.46 | |
| Inventory turnover | 5.95 | 2.66 | 1.3 | 4.07 | 1.09 | |
| ROE | -0.75 | -1.15 | -0.75 | -1.22 | -1.14 | |
| Capex per share | -0.2 | -0.19 | -0.05 | -0.1 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.04 | 0.03 | 0.03 | 0.01 | 0.01 | |
| Net income per share | -0.16 | -0.15 | -0.14 | -0.07 | -0.05 | |
| Operating cash flow per share | -0.13 | -0.18 | -0.17 | -0.06 | -0.04 | |
| Free cash flow per share | -0.13 | -0.18 | -0.17 | -0.06 | -0.04 | |
| Cash per share | 0.07 | 0.39 | 0.22 | 0.02 | 0.02 | |
| Book value per share | 0.18 | 0.61 | 0.46 | 0.11 | 0.05 | |
| Tangible book value per share | 0.05 | 0.52 | 0.37 | 0.08 | 0.03 | |
| Share holders equity per share | 0.18 | 0.61 | 0.46 | 0.11 | 0.05 | |
| Interest debt per share | 0.14 | 0.01 | 0.02 | 0 | 0 | |
| Market cap | 280.23M | 141.16M | 150.97M | 245.6M | 143.78M | |
| Enterprise value | 296.23M | 18.46M | 88.06M | 228M | 130.68M | |
| P/E ratio | -1.84 | -0.73 | -0.82 | -1.04 | -0.88 | |
| Price to sales ratio | 28.89 | 12.83 | 14.25 | 21.93 | 13.96 | |
| POCF ratio | -9.04 | -2.47 | -2.77 | -4.84 | -4.92 | |
| PFCF ratio | -8.98 | -2.44 | -2.73 | -4.84 | -4.92 | |
| P/B Ratio | 6.82 | 0.72 | 1.03 | 2.83 | 3.34 | |
| PTB ratio | 6.82 | 0.72 | 1.03 | 2.83 | 3.34 | |
| EV to sales | 30.54 | 1.68 | 8.31 | 20.36 | 12.69 | |
| Enterprise value over EBITDA | -9.53 | -0.41 | -2.03 | -3.85 | -3.23 | |
| EV to operating cash flow | -9.56 | -0.32 | -1.61 | -4.5 | -4.48 | |
| EV to free cash flow | -9.49 | -0.32 | -1.59 | -4.5 | -4.48 | |
| Earnings yield | -0.14 | -0.34 | -0.31 | -0.24 | -0.28 | |
| Free cash flow yield | -0.11 | -0.41 | -0.37 | -0.21 | -0.2 | |
| Debt to equity | 0.81 | 0.01 | 0.04 | 0 | 0 | |
| Debt to assets | 0.32 | 0.01 | 0.04 | 0 | 0 | |
| Net debt to EBITDA | -0.51 | 2.72 | 1.45 | 0.3 | 0.32 | |
| Current ratio | 1.1 | 7.9 | 6.96 | 3.7 | 1.29 | |
| Interest coverage | 29.75 | -28.83 | -33.16 | 0 | 0 | |
| Income quality | 0.87 | 1.1 | 1.17 | 0.86 | 0.72 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.36 | 2 | 1.34 | 1.46 | 1.55 | |
| Research and developement to revenue | 1.15 | 1.41 | 1.12 | 1.21 | 0.79 | |
| Intangibles to total assets | 0.3 | 0.13 | 0.15 | 0.22 | 0.23 | |
| Capex to operating cash flow | 0.01 | 0.01 | 0.02 | 0 | 0 | |
| Capex to revenue | -0.02 | -0.06 | -0.08 | 0 | 0 | |
| Capex to depreciation | -0.04 | -0.1 | -0.53 | 0 | 0 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| Graham number | 0.8 | 1.45 | 1.22 | 0.43 | 0.25 | |
| ROIC | -0.48 | -0.25 | -0.29 | -0.66 | -0.93 | |
| Return on tangible assets | -0.53 | -0.25 | -0.32 | -0.7 | -0.55 | |
| Graham Net | -0.08 | 0.43 | 0.27 | 0.02 | -0.02 | |
| Working capital | 6M | 162.8M | 117.18M | 56.7M | 15.4M | |
| Tangible asset value | 10.6M | 166.8M | 120.01M | 63.1M | 21.1M | |
| Net current asset value | 5.7M | 162.8M | 111.26M | 56.5M | 15.3M | |
| Invested capital | 0.81 | 0.01 | 0.04 | 0 | 0 | |
| Average receivables | 21.9M | 28M | 34.83M | 18.73M | 0 | |
| Average payables | 12.55M | 11.7M | 9.14M | 3.54M | 0 | |
| Average inventory | 18.05M | 19.75M | 26.12M | 34.47M | 40.45M | |
| Days sales outstanding | 220.82 | 263.45 | 318.03 | 0 | 0 | |
| Days payables outstanding | 163.88 | 85.42 | 73.86 | 0 | 0 | |
| Days of inventory on hand | 220.3 | 176.19 | 303.83 | 351.18 | 278.12 | |
| Receivables turnover | 0.41 | 0.34 | 0.28 | 0 | 0 | |
| Payables turnover | 0.55 | 1.05 | 1.22 | 0 | 0 | |
| Inventory turnover | 0.41 | 0.51 | 0.3 | 0.26 | 0.32 | |
| ROE | -0.93 | -0.25 | -0.32 | -0.68 | -0.95 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
IRRAS.ST Frequently Asked Questions
What is IRRAS AB (publ) stock symbol ?
IRRAS AB (publ) is a SE stock and trading under the symbol IRRAS.ST
What is IRRAS AB (publ) stock quote today ?
IRRAS AB (publ) stock price is $0.1604 today.
Is IRRAS AB (publ) stock public?
Yes, IRRAS AB (publ) is a publicly traded company.
Company Profile
- Volume Average 551.32K
- Market Capitalization 181.75M
- Employee 47
- CEO Mr. Will Martin
- Headquarters Stockholm,SE
- IPO Date 2017-11-22
-
Website
https://www.irras.com 
IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to enhance the lives of critically ill patients worldwide. It designs, develops, and commercializes neurocritical care products that transform patient outcomes and addresses complications associated with current treatment methodologies. The company offers IRRAflow, an irrigating intracranial drainage system that combines controlled drainage, automated irrigation, and integrated monitoring of intracranial pressure (ICP) for the treatment of patients suffering from hemorrhagic strokes and chronic subdural hematoma. It also provides Hummingbird ICP monitoring system comprising Hummingbird ICP Control Module (HICP200) and the related catheters, which include Hummingbird Quad ICP monitoring with drainage (H610), and Hummingbird Solo ICP monitoring (H110); and Hummingbird neuromonitoring products to manage patients suffering from conditions that cause an elevated intracranial pressure, including traumatic brain injury, subarachnoid hemorrhage, and strokes. It markets and sells its products to hospitals through its direct sales force and a network of distribution partners. IRRAS AB (publ) was incorporated in 2011 and is headquartered in Stockholm, Sweden.
